Farah Jivraj

Head of Market Access, Policy & Stakeholder Relations

BIOGEN CANADA

Farah Jivraj is currently the Head of Market Access and stakeholder relations for Biogen Canada. After receiving her Pharmacy degree and M.Sc. in Health Economics & Health Policy degree from England, Farah worked in South East Asia training Government officials on Health Economics and Policy. Over the last 20 years, Farah has had significant experience in the Health industry, at large Pharmaceutical companies, such as Sanofi Genzyme and Janssen, as well as Biotechnology companies in leadership positions in Medical Affairs, Government & Access and Health Economics. Farah has provided strong leadership and strategic direction on Health Policy and access related functions working with Governments and Private Insurers.  She has built relationships with Health Technology Assessment experts to create an optimal Canadian environment to adopt innovative therapies.

 

Beyond the office, Farah is an active member of her community.  She was the Vice Chair for Focus Humanitarian Assistance Canada that helps communities prepare for national and manmade disasters and continues to volunteer in the community. Farah has presented at various leadership conferences on global drug initiatives and cost effectiveness. Farah has one son and resides in the Queen west area of Toronto.


All Sessions by Farah Jivraj

Printer Friendly See Full Agenda

Agenda: Day 1 Oct 5, 2020

3:00 pm

3:00 pm

PANEL DISCUSSION: Drugs for Rare Diseases

Critical Elements for a National Strategy and Framework

With Health Canada preparing for the development and implementation of a national strategy for high-cost drugs for rare diseases, what can we learn from the COVID-19 vaccine journey? Leverage the experience of these market leaders to inform your market access strategy. Establish your game plan by:

  • Determining the types of partnerships and funding that will be key to the successful development of drugs for rare diseases
  • Analyzing the impact of recently increased government funding on the overall treatment pipeline
  • Visualizing potential safe and expeditious routes to commercialization for these medicines

Chart a course to succeed in the new market access model for rare disease therapies

Agenda: Day 2 Oct 6, 2020